RRML - The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- October 2025 -
 
Romanian Review of Laboratory ... 15
Comparison of platelet suspens... 12
The diagnostic value of lipopr... 11
Polymorphisms in FVL, prothrom... 11
Investigation of cytokine chan... 10
Unlocking the future of breast... 10
Evaluation of the impact of vi... 9
Serum fibronectin and C-reacti... 8
Plasma phosphorylated neurofil... 8
Species distribution and resis... 8

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 28(1)/2020 DOI:10.2478/rrlm-2020-0001
XML
TXT

Research article

The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer

Orsolya Mártha, Daniel Balan, Daniel Porav-Hodade, Emőke Drágus, Mihai Dorin Vartolomei, Călin Bogdan Chibelean, Angela Borda, Ákos Pytel, Olivér Árpád Vida

Correspondence should be addressed to: Daniel Balan

Abstract:

Introduction: The peritumoral inflammatory reaction has a substantial importance in the oncologic outcome of bladder cancer (BC). One biomarker proven to be practical and accessible is the NLR (neutrophil-to-lymphocyte ratio) for high risk non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the role of NLR as a prognostic biomarker for disease recurrence, progression and survival of pTa NMIBC. Material and Methods: In our retrospective study we included 54 patients with pTa NMIBC from a total of 235 patients who underwent transurethral resection of bladder tumor (TURBT) during two consecutive years: January 2007 - December 2008 [median follow-up 106 months (interquartile range-IQR 68-116)]. Criteria for inclusion were: primary tumor, low-grade, with NLR available at 2 weeks prior to TURBT. NLR was considered altered if higher than 3. Results: The median age of the patients included was 63 years (IQR 55 - 72). Most of the patients had NLR<3 (37 patients). Median EORTC (European Organization of Research and Treatment of Cancer) Recurrence Score was 4 (IQR 1-6), while EORTC Progression Score was 3 (IQR 0-6), respectively. Recurrence occurred in 8 out of 54 (14.81 %) patients and progression was identified in 2 out of 54 (3.70 %) patients with muscle-invasive BC during follow-up. NLR>3 was not associated with clinical and pathological factors. In multivariable Cox regression analyses NLR as a continuous variable was an independent predictive factor for recurrence. Recurrence-free survival (RFS) Kaplan-Meier analysis did not show a statistical significance between NLR groups: 82.67% vs. 64.12%, p=0.26. Kaplan-Meier analysis showed a lower Progression-free survival (PFS) in the NLR>3 group: 94.12% vs. 100%, p=0.04. During follow-up (106 months) 18 patients deceased with no impact of NLR as a prognostic factor in multivariable analyses. Kaplan-Meier overall survival (OS) analysis showed a 10-year OS of 70.27% in the low NLR group compared with 58.82% in the high NLR group, p=0.45. Conclusion: In this cohort, high NLR was associated with high recurrence rate in patients with Ta NMIBC. In low-risk NMIBC NLR could represent a valid biomarker for clinical usage regarding the intensity of follow-up schedule.

Keywords: neutrophil-to-lymphocyte ratio, non-muscle invasive bladder cancer, transurethral resection of bladder tumor, recurrence-free survival, progression-free survival

Received: 12.8.2019
Accepted: 30.10.2019
Published: 21.11.2019

 
  PDF Download full text PDF
(417 KB)
     
 
How to cite
Mártha O, Balan D, Porav-Hodade D, Drágus E, Vartolomei MD, Chibelean CB, et al. The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer. Rev Romana Med Lab. 2020;28(1):29-38. DOI:10.2478/rrlm-2020-0001